| Ytd | 11.43% | |
| 1y | -14.29% |
| Open | 1.56 | Prev Close | 1.56 | Low | 1.53 | High | 1.62 | Mkt Cap | 69.48M |
| Vol | 275.99K | Avg Vol | 815.42K | EPS | -1.02 | P/E | -1.53 | Forward P/E | 2.57 |
| Beta | -0.83 | Short Ratio | 1.22 | Inst. Own | 0.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.76 | 200-d Avg | 1.63 | 1yr Est | 12.67 |
OSTX News
Roth Capital analyst Adam Walsh initiates coverage on OS Therapies (AMEX:OSTX) with a Buy rating
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs p
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the
OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no ne
Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the pric
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst con
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune
New patent application covers treatment-emergent immune signature related to 'turning cold tumor
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst con
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with ex
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated
OS Therapies shares climb after new regulatory plans for OST-HER2 osteosarcoma treatment in the UK,
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in
